Capital Advisors Inc. OK Decreases Holdings in Edwards Lifesciences Co. (NYSE:EW)

Capital Advisors Inc. OK lowered its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 45.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 5,932 shares of the medical research company's stock after selling 4,887 shares during the quarter. Capital Advisors Inc. OK's holdings in Edwards Lifesciences were worth $439,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Harbor Capital Advisors Inc. increased its holdings in Edwards Lifesciences by 2.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company's stock valued at $824,000 after purchasing an additional 273 shares during the period. Nordea Investment Management AB grew its position in shares of Edwards Lifesciences by 34.6% in the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company's stock worth $301,355,000 after buying an additional 1,043,484 shares during the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST increased its stake in shares of Edwards Lifesciences by 6.7% during the fourth quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company's stock valued at $355,344,000 after buying an additional 300,000 shares during the period. Sivik Global Healthcare LLC bought a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $3,702,000. Finally, Avanza Fonder AB purchased a new stake in Edwards Lifesciences in the fourth quarter worth $4,845,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

NYSE:EW traded up $0.23 during trading hours on Friday, reaching $76.23. The company had a trading volume of 3,899,190 shares, compared to its average volume of 4,438,355. The firm has a market cap of $44.96 billion, a price-to-earnings ratio of 11.00, a PEG ratio of 3.64 and a beta of 1.10. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm's 50 day moving average price is $72.67 and its 200-day moving average price is $69.54.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. On average, analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $74.08, for a total transaction of $185,200.00. Following the transaction, the vice president now owns 23,189 shares of the company's stock, valued at $1,717,841.12. The trade was a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the company's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares of the company's stock, valued at approximately $4,613,628.24. The trade was a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 26,489 shares of company stock valued at $2,002,829. Insiders own 1.29% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on EW. Bank of America raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $82.00 to $90.00 in a research report on Monday, December 16th. Morgan Stanley increased their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Wednesday. JPMorgan Chase & Co. lifted their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the company a "neutral" rating in a research report on Friday, October 25th. Canaccord Genuity Group raised their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research note on Thursday. Finally, Barclays upped their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.